2019-09-05T13:26:05-05:00 2018-12-31 WITHUMSMITHBROWNPC 4600 EAST WEST HWY 900 BETHESDA MD 208143423 990 2018-01-01 042531031 NATIONAL FOUNDATION FOR CANCER RESEARCH % KWOK LEUNG NATI 3016541250 5515 SECURITY LANE Suite 1105 ROCKVILLE MD 20852 SUJUAN BA PRESIDENT & CEO 3016541250 2019-09-04 true RICHARD L RUVELSON P00234075 3012726000 2019-09-04 209.190.253.84 22006220192485000168 2019-09-05 P 833D9BA5299041826641AEDE5C1773806529F77E EBD8DFBC700724A96E49BF1A406FB658268A8823 2018 2019-02-21 02:37:17Z SUJUAN BA 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 14845391 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 8 8 32 100 7769 28717 11921451 12714798 0 0 740805 724768 296389 257329 12958645 13696895 2704783 3998229 0 0 2584611 2859084 50237 51649 2708060 8092769 8238769 13432400 15147731 -473755 -1450836 14949937 13294160 2043145 2997583 12906792 10296577 X SEE SCHEDULE O false false 5627446 3998229 CANCER RESEARCH - SEE SCHEDULE O 5563306 CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O 11190752 true true false false false true false false false true true false false true true true false true false false false false true true true false false true true true false false false false false false false false true false false false false true false false false true 30 0 true 32 true true true true HK false false false true true false false false false false false false false false X 8 8 true false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X KWOK LEUNG 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 X JOSEPH F FRANLIN CHAIR 10.0 0.0 X X 0 0 0 WENDI P DENNARD TREASURER 2.0 0.0 X X 0 0 0 JUDITH P BARNHARD DIRECTOR 2.0 0.0 X 0 0 0 MICHAEL BURKE DIRECTOR 2.0 0.0 X 0 0 0 PADMAKUMAR KAIMAL DIRECTOR 2.0 0.0 X 0 0 0 GUS KODERSHA DIRECTOR (AS OF 5/2018) 2.0 0.0 X 0 0 0 WILLIAM SCANDONE DIRECTOR (AS OF 5/2018) 2.0 0.0 X 0 0 0 EDWARD S WEST DIRECTOR 2.0 0.0 X 0 0 0 FRANKLIN C SALISBURY JR CHIEF EXECUTIVE OFFICER 40.0 2.0 X 309915 0 71685 SUJUAN BA PRESIDENT/COO 40.0 5.0 X 318810 0 72099 KWOK LEUNG CFO/SECRETARY 40.0 5.0 X 179493 0 28603 YI WANG CHIEF STRTGY OFF. - ALLIANCES 40.0 1.0 X 202005 0 32493 BRIAN WACHTEL SR. DIR. PARTNERSHIPS & EVENTS 40.0 0.0 X 109178 0 13972 BRADLEY GILLENWATER SR. DIR. COMMUNICATIONS 40.0 2.0 X 108907 0 12886 1228308 0 231738 6 false true false REDFIELD DIRECT LLC 11422 MIRACLE HILLS DR 450 OMAHA NE 68154 LABEL PRINTING 1026067 CALMARK GROUP LLC 6755 S SAYRE AVE BEDFORD PARK IL 60638 MAILSHOP 776111 CP DIRECT INC 4600 A BOSTON WAY LANHAM MD 20706 PRINTING 624044 KEY ACQUISITION PARTNERS 181 HARRY S TRUMAN PKWY 265 ANNAPOLIS MD 21401 LIST BROKER 536661 MACKAY MITCHELL ENVELOPE CO 2100 ELM ST SE MINNEAPOLIS MN 55414 ENVELOPE PRINTING 452567 9 59730 351748 12303320 253295 12714798 0 293923 293923 0 14936 14936 0 0 0 1517019 1086174 430845 430845 430845 36978 351748 62322 -25344 -25344 0 0 0 0 0 0 MAILING LIST RENTALS 541800 267737 7769 259968 267737 13696895 7769 974328 3784543 3784543 203686 203686 10000 10000 0 980605 798678 174202 7725 0 1519461 1073867 222441 223153 109055 70060 16269 22726 95110 50993 32674 11443 154853 114924 24735 15194 0 134004 11111 122893 42520 42520 0 51649 51649 65816 65816 249537 107244 142293 129253 128810 443 294652 84901 188930 20821 421220 290449 4014 126757 0 243669 182012 37618 24039 47935 19546 28389 0 69877 69877 0 0 35941 26661 5753 3527 38649 28657 6183 3809 DIRECT MAIL PROGRAMS 6268258 4146956 2121302 LOCK BOX SERVICE 121989 82068 39921 PROCESS FEES-LIST SALES 51046 34519 16527 MAJOR GIFT 19832 808 19024 4571 4571 15147731 11190752 1248919 2708060 X 6740146 4664361 2075785 1000 1000 2565486 1167990 0 0 119157 106247 0 0 0 0 0 0 0 0 424444 583645 387823 250006 123318 137817 9104342 7370729 442 442 0 0 0 0 2611748 3926290 14949937 13294160 2034818 1311474 0 0 8327 135 0 0 0 0 0 0 0 0 0 0 0 1685974 2043145 2997583 X 9308044 7141083 1433990 1213987 2164758 1941507 12906792 10296577 14949937 13294160 -1450836 -1159379 X false true X true false X 14884024 13729474 13952247 11921451 12714798 67201994 0 0 14884024 13729474 13952247 11921451 12714798 67201994 0 67201994 334775 372780 287499 296562 308859 1600475 7420 16841 9182 647 34090 363577 341191 348604 284518 259968 1597858 70434417 0.95411 0.94651 X 1 0 0 3040 true true 8699102 7119860 -271815 5150164 10396983 8164316 3394266 213282 3072762 8699102 7627682 3687809 22308 3173483 8164316 7771063 3491261 -158768 3475874 7627682 7621530 3324595 142232 3317294 7771063 0.67860 0.18670 0.13470 false false 26890 2739 24151 360933 247267 113666 137817 AMOUNT HELD IN TRUST BY OTHERS 2339933 RIGHT OF USE ASSET 1586357 3926290 0 LEASE LIABILITY 1685974 1685974 X 12594665 -1159379 20000 111000 -1028379 13623044 65816 8035 73851 13696895 15436106 20000 342226 362226 15073880 65816 8035 73851 15147731 PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FIN 48 FOOTNOTE: ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA REQUIRE MANAGEMENT TO EVALUATE INCOME TAX POSITIONS TAKEN AND ACCRUE AN INCOME TAX LIABILITY IF THE ORGANIZATION HAS TAKEN AN UNCERTAIN POSITION THAT MORE LIKELY THAN NOT WOULD NOT BE SUSTAINED UPON EXAMINATION BY TEH INTERNAL REVENUE SERVICE. MANAGEMENT HAS EVALUATED THE INCOME TAX POSITIONS TAKEN AND CONCLUDED THAT AS OF DECEMBER 31, 2018 THERE ARE NO UNCERTAIN POSITIONS TAKEN OR EXPECTED TO BE TAKEN THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS. THE NJCR AND AFFILIATES ARE SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS IN PROGRESS FOR ANY TAX PERIODS. IN ADDITION, THERE HAVE BEEN NO TAX RELATED INTEREST OR PENALTIES FOR THE PERIOD PRESENTED IN THESE FINANCIAL STATEMENTS. SHOULD SUCH PENALTIES AND INTEREST BE INCURRED, THE FOUNDATION'S POLICY IS TO RECOGNIZE THEM AS GENERAL AND ADMINISTRATIVE EXPENSES ON THE STATEMENT OF ACTIVITIES. PART XI, LINE 2D - OTHER REVENUES INCLUDED ON FINANCIALS, NOT FORM 990: $111,000 - RELATED ORGANIZATIONS' REVENUES PART XI, LINE 4B - OTHER $8,035 - FOREIGN TAXES WITHHOLDING ON INVESTMENT INCOME DEDUCTED FROM REVENUES ON FINANCIAL STATEMENTS PART XII, LINE 2D - OTHER EXPENSES INCLUDED ON FINANCIALS, NOT FORM 990: $342,226 - RELATED ORGANIZATIONS' EXPENSES PART XII, LINE 4B - OTHER $8,035 - FOREIGN TAXES WITHHOLDING ON INVESTMENT INCOME DEDUCTED FROM REVENUES ON FINANCIAL STATEMENTS RESEARCH REVIEW Europe (Including Iceland and Greenland) 1 5000 CHECK RESEARCH REVIEW East Asia and the Pacific 1 5000 CHECK false false false false false false X X X X X X true MERKLE INC 7001 COLUMBIA GATEWAY DRIVE COLUMBIA MD 21046 DIRECT MAIL COUNSEL false 6514714 51649 6463065 6514714 51649 6463065 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WY DAFFODILS 123259 86281 36978 19437 3920 1889 PLAY 4 THE CURE 211207 211207 21408 50 54260 54260 15668 388726 351748 36978 19437 3920 38965 62322 -25344 true THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 445 NORTH FIFTH ST SUITE 600 PHOENIX AZ 85004 753065445 501(c)(3) 98413 RESEARCH CONTRACTS ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(c)(3) 93652 47159 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(c)(3) 86437 RESEARCH CONTRACTS DANA-FARBER CANCER INSTITUTE 44 BINNEY ST MAIL STOP L229 BOSTON MA 02115 042263040 501(c)(3) 100000 RESEARCH CONTRACTS MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(c)(3) 312790 44987 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(c)(3) 100000 RESEARCH CONTRACTS UNIVERSITY OF TEXAS - MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 77210 746001118 501(c)(3) 39889 RESEARCH CONTRACTS UNIVERSITY OF MARYLAND 220 ARCH ST OFFICE LEVEL 2 BALTIMORE MD 21201 526002033 501(c)(3) 100000 RESEARCH CONTRACTS VIRGINIA COMMONWEALTH UNIVERSITY PO BOX 980568 RICHMOND VA 23298 546001758 501(C)(3) 100000 20000 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 86242 RESEARCH CONTRACTS UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 19104 231352685 501(C)(3) 100000 15000 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS SCOTTSDALE HEALTHCARE CORP 8125 N HAYDEN RD SCOTTSDALE AZ 85258 942735850 501(C)(3) 87800 CANCER HOTLINE WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501(C)(3) 113645 20000 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS INVAMET THERAPEUTICS LLC 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 821967545 225000 TRANSLATIONAL NONPARIEL BIOTECHNOLOGIES LLC 2010 CORPORATE RIDGE MCLEAN VA 22102 475684209 125000 TRANSLATIONAL ONCOKIDS BIOSCIENCES 43 KENT ST 1 BROOKLINE MA 02445 823410836 100000 TRANSLATIONAL STROMATIS PHARMA LLC 225 GARLAND HILL DR ATHENS GA 30605 822219124 125000 TRANSLATIONAL INTERLEUKIN COMBINATORIAL THERAPIES INC 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 823395941 200000 TRANSLATIONAL GLOBAL COALITION FOR ADAPTIVE RESEARCH INC PO BOX 427 LEXINGTON MA 02420 821199380 501(C)(3) 562688 RESEARCH CONTRACTS SILCSBIO LLC 8 MARKET PLACE 300 BALTIMORE MD 21230 455174923 100000 TRANSLATIONAL TVARDI THERAPEUTICS INC 7000 FANNIN STREET 1960M HOUSTON TX 77030 823784554 500000 TRANSLATIONAL YIVIVA INC 447 BROADWAY 2F NEW YORK NY 10013 811602368 100000 TRANSLATIONAL VITANOVA BIOMEDICAL INC 222 SID BAKER ST 365 KERRVILLE TX 78028 471205206 25000 TRANSLATIONAL 14 9 CANCER RESEARCH 4 111029 RESEARCH REVIEW 4 65000 CANCER RESEARCH REWARD 2 25000 TRAVEL FOR CANCER RESEARCH EVENT 5 2657 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X X false false false false false false false false false FRANKLIN C SALISBURY JR CHIEF EXECUTIVE OFFICER 308727 0 0 1188 53000 0 18685 0 381600 0 0 0 SUJUAN BA PRESIDENT/COO 318036 0 0 774 53000 0 19099 0 390909 0 0 0 KWOK LEUNG CFO/SECRETARY 178719 0 0 774 26808 0 1795 0 208096 0 0 0 YI WANG CHIEF STRTGY OFF. - ALLIANCES 200817 0 0 1188 30178 0 2315 0 234498 0 0 0 X 13 106151 stock market value X CHEMICALS & MATERIALS 6 147146 FMV false true false PART III, LINE 1 - ORGANIZATION'S MISSION: THE NATIONAL FOUNDATION FOR CANCER RESEARCH ("NFCR") IS A LEADING PUBLIC CHARITY DEDICATED TO FUNDING CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO CANCER PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, CURES FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. SINCE 1973, NFCR HAS PROVIDED MORE THAN $380 MILLION IN SUPPORT OF DISCOVERY-ORIENTED CANCER RESEARCH FOCUSED ON UNDERSTANDING HOW AND WHY CELLS BECOME CANCEROUS, AND ON PUBLIC EDUCATION RELATING TO CANCER PREVENTION, DETECTION, AND TREATMENT. NFCR SCIENTISTS ARE DISCOVERING CANCER'S MOLECULAR MYSTERIES AND TRANSLATING THEIR DISCOVERIES INTO THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT OF MILLIONS OF DONORS NATIONWIDE. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO OUR ULTIMATE GOAL-CURING CANCER, ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG. PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS: HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ======================================== With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead to a cure for this deadly disease. A FEW OF THE KEY PROGRESSES ACHIEVED BY NFCR SCIENTISTS IN 2018: 20 Cancer biomarkers identification or evaluation of genetic pieces of cancers vulnerabilities that may lead doctors to earlier diagnoses and precision treatments. 8 New drug candidates and potential therapeutics identification of anticancer agents that could lead to new treatment options desperately needed by patients. 19 Cancer-Related genes and proteins discovery and further exploration of key cancer molecules which could provide new targets for drug development. NOTABLE RESEARCH HIGHLIGHTS ============================== Identifying Patients Likely to Respond to Immunotherapy -------------------------------------------------------- Immunotherapy for metastatic melanoma remarkably increases survival for some patients beyond ten years. For others, the response is minimal and ineffective treatment may continue before standard tests confirm the lack of response. Monitoring an early response to immunotherapy is a challenge. Assessing local immune response from invasive serial tumor biopsies from single metastatic sites may not represent other metastatic sites - the tumor burden - in melanoma, a cancer caused by various genes. To address this challenge, Dr. Daniel Habers team will use their previously developed liquid biopsy blood test that captures circulating tumor cells (CTCs) shed from all tumor sites and present in patients blood samples. They have discovered a signature panel of 19 RNA molecules expressed in captured melanoma CTCs that can be 'scored' to measure tumor burden in response to therapy. CTC RNA scoring blood test at 7 weeks of therapy correlated with marked improvement in survival without tumor growth. Early assessment of treatment response can guide application of immunotherapy. Moreover, CTC RNA signatures may also be identified in other cancers. Daniel Haber, M.D., Ph.D. Combination Therapy for Resistant Lung Cancer ---------------------------------------------- The cornerstone of treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) is 'on target' therapies targeting the cancer-promoting ALK proteins. These therapies have dramatically improved the outlook for patients, but, eventually, almost all patients will develop resistance. their tumors will have developed 'off-target' mechanisms of resistance that activate downstream growth signaling pathways bypassing ALK. To develop a treatment for 'off-target' resistance, a panel of resistant cell lines derived from patients screened with an RNA library identified is Shp2 protein. A Shp2 inhibitor combined with on-target ALK inhibitor in patient-derived cell lines inhibited cancer cell growth. After efficacy of the two drugs is established in pre-clinical models, a first-in-man phase 1 clinical trial treating ALK-positive NSCLC patients will determine if the combination therapy can overcome resistance. Combination therapy could become a front-line therapy, and improve the chance of a durable and complete remission bringing patients one step closer to a cure. Alice T. Shaw, M.D., Ph.D. New Approaches to Treating Pancreatic Cancer --------------------------------------------- Pancreatic cancer, the 3rd leading cause of cancer death in the U.S., has a 5-year survival rate of less than 9%. One reason current treatments have limited activity is tumors are surrounded by stroma - dense fibrotic tissue of immune cells, fat cells, stem cells, fibroblasts and other cells. Stroma interacts with cancer cells, contributing to its aggressiveness and drug resistance. Also, pancreatic cancer cells themselves undergo the EMT (Epithelial-Mesenchymal Transition) process that allows the cells to metastasize and resist treatment. NFCR scientists are developing new treatments for pancreatic cancer by targeting the stroma and the EMT process. With biopsy samples from human tumors and lab models, single cell RNA sequencing identifies all RNA expressed in individual cells, revealing the distinct cell types and signaling pathways that characterize each cell population. From these results, therapies better tailored to a patients tumor are being selected to treat pancreatic cancer patients in a pilot clinical trial. EMT inhibitors are first tested in an EMT assay using zebrafish as a model, before testing in pancreatic cancer models. In this era of precision oncology, the best drugs matched to the individuals targets may further improve care of pancreatic cancer patients who have no other options. Daniel Von Hoff, M.D. Making Inroads to Defeat Metastasis ------------------------------------- At least 90% of cancer deaths are due to a tumors spread or metastasis to vital organs in our body. Dr. Danny Welch, with NFCR funds, has previously discovered eight of the 35 known metastasis suppressor genes. In metastasis, many of these genes are under-expressed and produce minimal or non-existent levels of their proteins, allowing cancer to spread. In KISS1 and BRMSI genes, his team has identified domains (small regions) in each protein that are crucial in suppressing metastasis and interacting with potential protein partners. The idea is to develop small molecules that mimic the activity of the domains and can function as a complete protein to suppress metastasis. In other research, Dr. Welch has developed a complex metastasis cancer model wherein small genetic changes (single nucleotide polymorphisms) may better explain racial disparities in tumor development, as well as better predict metastasis and patient survival. A genetic test on a patients blood sample may help doctors plan treatments more carefully. Danny R. Welch, Ph.D. Research Identifies Potential Guidance for Gastric Cancer Treatment ------------------------------------------------------------------- Researchers from Wake Forest Baptist Medical Center and Tianjin Medical University Cancer Institute and Hospital (TMUCIH) have discovered that gastric cancer tissue samples bearing mutation of a specific gene, MUC16, too are associated with higher tumor mutation loads. Also known as tumor mutation burdens, measurement of high genetic mutation rates among cancerous versus healthy tissue has increasingly been shown to correlate with effective response rates to immunotherapy. The knowledge could bode positively for patients with the biomarker present. Tumors with higher tumor mutation loads tend to be more responsive to immunotherapy. The authors stress the implications that this and other proven biomarkers have on the ability of oncologists to design cancer treatments most likely to succeed. Findings from this study, for example, could serve to open immunotherapy options for up to 38% of gastric cancer patients. Wei Zhang, Ph.D. Attacking Metastatic Tumors in the Brain ------------------------------------------ A discovery by NFCR scientists and collaborators could be very important for patients whose cancers have spread to the brain. About 25% of all breast cancers have an excess of Human Epidermal Growth Factor Receptor 2 (known as HER 2positive or HER2+) which spreads more quickly than other types of breast cancer. HER2+ targeted therapies treat HER2+ breast cancer and patients are in remission for years or longer. However, up to 50% of these patients receiving these targeted therapies eventually develop brain metastases, which are inevitably fatal. Research with tumor models and human cancer samples has determined breast-cancer-associated brain lesions overexpress another related factor, HER3, and that inhibiting HER3 could help overcome treatment resistance. Importantly, HER2 targeted therapy combined with inhibitors to HER3 significantly slowed brain metastatic tumor growth and improved survival in tumor models. This discovery could have a substantial impact on the future development of therapeutic strategies and ultimately, patient survival from this deadly disease. Moreover, since HER3 expression is associated with treatment resistance in several types of cancer, this discovery could potentially benefit a much broader group of patients. Rakesh Jain, Ph.D. PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: NFCR provides the public with free publications containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message mailed to tens of millions of families and reaching tens of thousands of individuals through our social media channels (twitter and facebook) and through our blogs, helps to assure that fewer of todays healthy individuals will get cancer and more of todays cancer patients will become tomorrows cancer survivors. Our public education materials include early cancer detection guide, a Childhood Cancer Chart, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. PART VI, SECTION A, LINE 2 - DIRECTORS/OFFICERS WITH FAMILY RELATIONSHIPS: FRANKLIN SALISBURY, CEO, AND SUJUAN BA, PRESIDENT/COO, ARE HUSBAND AND WIFE. PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENSE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEALINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMEBER'S REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. PART IX, LINE 26, JOINT COSTS ALLOCATION: NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 40 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY EMAIL, POSTAL EMAIL, PHONE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. DARWIN FOUNDATION 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 371473821 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR true RESEARCH FOR A CURE 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 010744146 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR true false false false false false false false false false false false false false true true false false true false DARWIN FOUNDATION R 100000 CASH